Adiponectin Inhibits Cell Proliferation by Interacting with Several Growth Factors in an Oligomerization-dependent Manner
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Adiponectin, an adipocyte-specific secretory protein, is present in serum as three oligomeric complexes. Apart from its roles as an anti-diabetic and anti-atherogenic hormone, adiponectin has been implicated as an important regulator of cell growth and tissue remodeling. Here we show that some of these functions might be mediated by the specific interactions of adiponectin with several important growth factors. Among six different growth factors examined, adiponectin was found to bind with platelet-derived growth factor BB (PDGF-BB), basic fibroblast growth factor (FGF), and heparin-binding epidermal growth factor-like growth factor (HB EGF) with distinct affinities. The bindings of adiponectin with these growth factors are oligomerization-dependent. PDGF-BB bound to the high molecular weight (HMW) and middle molecular weight (MMW) complexes, but not to the low molecular weight (LMW) complex of adiponectin. Basic FGF preferentially interacted with the HMW form, whereas HB EGF bound to all three forms with comparable affinities. These three growth factors did not compete with each other for their bindings to adiponectin, suggesting the involvement of distinct binding sites. The interactions of adiponectin with PDGF-BB, basic FGF, and HB EGF precluded the bindings to their respective membrane receptors and attenuated the DNA synthesis and cell proliferation induced by these growth factors. Small interfering RNA-mediated down-regulation of adiponectin receptors did not affect the suppressive effects of adiponectin on cell proliferation stimulated by these growth factors. These data collectively suggest that the oligomeric complexes of adiponectin can modulate the biological actions of several growth factors by controlling their bioavailability at a pre-receptor level and that this effect might partly account for the anti-atherogenic, anti-angiogenic, and anti-proliferative functions of adiponectin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes
Scherer, P. E., Williams, S., Fogliano, M., Baldini, G., & Lodish, H. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26746 · Cited by 3,237
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity
Hu, E., Liang, P., & Spiegelman, B. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10697 · Cited by 2,238
Novel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin
Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., et al. (1999) · Circulation · doi:10.1161/01.cir.100.25.2473 · Cited by 2,147
Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., & Matsubara, K. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0587 · Cited by 2,083
Fruebis, J., Tsao, T., Javorschi, S., Ebbets-Reed, D., Erickson, M., Yen, F. T., Bihain, B. E., & Lodish, H. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041591798 · Cited by 1,985
Cited by
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1937 · Cited by 3,188
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Adipose tissue in control of metabolism
Luo, L., & Liu, M. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0211 · Cited by 693
The Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 640
Adipose Tissue: The New Endocrine Organ? A Review Article
Wozniak, S. E., Gee, L. L., Wachtel, M. S., & Frezza, E. E. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0585-3 · Cited by 588
The Role of Adipose Tissue and Adipokines in Obesity-Related Inflammatory Diseases
Balistreri, C. R., Caruso, C., & Candore, G. (2010) · Mediators of Inflammation · doi:10.1155/2010/802078 · Cited by 550
Adiponectin and cancer: a systematic review
Kelesidis, I., Kelesidis, T., & Mantzoros, C. S. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603051 · Cited by 487
Relationships between fat and bone
Reid, I. R. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0492-z · Cited by 475
Koerner, A., Kratzsch, J., & Kiess, W. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.008 · Cited by 471
Yanai, H., & Yoshida, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051190 · Cited by 468
Inflammation in Diabetic Nephropathy
Lim, A. K. H., & Tesch, G. H. (2012) · Mediators of Inflammation · doi:10.1155/2012/146154 · Cited by 437
Post-translational modifications of adiponectin: mechanisms and functional implications
Wang, Y., Lam, K. S. L., Yau, M.-H., & Xu, A. (2008) · Biochemical Journal · doi:10.1042/bj20071492 · Cited by 407
Self-citationAdipose Tissue and Atherosclerosis: Exploring the Connection
Fantuzzi, G., & Mazzone, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.106.131755 · Cited by 384
Hansmann, G., Wagner, R. A., Schellong, S., de Jesus Perez, V. A., Urashima, T., Wang, L., Sheikh, A. Y., Suen, R. S., Stewart, D. J., & Rabinovitch, M. (2007) · Circulation · doi:10.1161/circulationaha.106.663120 · Cited by 366
Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells
Dieudonne, M.-N., Bussiere, M., Dos Santos, E., Leneveu, M.-C., Giudicelli, Y., & Pecquery, R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.076 · Cited by 347
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence
Barb, D., Williams, C. J., Neuwirth, A. K., & Mantzoros, C. S. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.858s · Cited by 338
Adipose tissue, obesity and adipokines: role in cancer promotion
Booth, A., Magnuson, A., Fouts, J., & Foster, M. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0037 · Cited by 329
Adiponectin actions in the cardiovascular system
HOPKINS, T., OUCHI, N., SHIBATA, R., & WALSH, K. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.009 · Cited by 327
Yau, S. Y., Li, A., Hoo, R. L. C., Ching, Y. P., Christie, B. R., Lee, T. M. C., Xu, A., & So, K.-F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415219111 · Cited by 326
“Adiponectin exists in the circulation primarily as three oligomeric complexes, including trimers, hexamers, or high molecular weight (HMW) oligomers (6, 7).”
BackgroundSelf-citationStojsavljević, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18070 · Cited by 325
Central Adiposity and Risk of Barrett’s Esophagus
Edelstein, Z. R., Farrow, D. C., Bronner, M. P., Rosen, S. N., & Vaughan, T. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.026 · Cited by 300
Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention
Zhu, W., Cheng, K. K. Y., Vanhoutte, P. M., Lam, K. S. L., & Xu, A. (2008) · Clinical Science · doi:10.1042/cs20070347 · Cited by 291
Self-citationAdiponectin and cardiovascular health: an update
Hui, X., Lam, K. S., Vanhoutte, P. M., & Xu, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01395.x · Cited by 286
Self-citationAdiponectin receptor signalling in the brain
Thundyil, J., Pavlovski, D., Sobey, C. G., & Arumugam, T. V. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01560.x · Cited by 280
Lin, Z., Pan, X., Wu, F., Ye, D., Zhang, Y., Wang, Y., Jin, L., Lian, Q., Huang, Y., Ding, H., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015308 · Cited by 271
Self-citationWang, Y., Lam, J. B., Lam, K. S. L., Liu, J., Lam, M. C., Hoo, R. L. C., Wu, D., Cooper, G. J. S., & Xu, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1969 · Cited by 270
Self-citationPerivascular adipose tissue: More than just structural support
Szasz, T., & Webb, R. C. (2012) · Clinical Science · doi:10.1042/cs20110151 · Cited by 265
Hypoadiponectinemia as a Predictor for the Development of Hypertension: A 5-Year Prospective Study
Chow, W.-S., Cheung, B. M. Y., Tso, A. W. K., Xu, A., Wat, N. M. S., Fong, C. H. Y., Ong, L. H. Y., Tam, S., Tan, K. C. B., Janus, E. D., et al. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.086835 · Cited by 264
Self-citationFat as an Endocrine Organ: Relationship to the Metabolic Syndrome
Hutley, L., & Prins, J. B. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00005 · Cited by 262
Wang, Y., Lam, K. S. L., Chan, L., Chan, K. W., Lam, J. B. B., Lam, M. C., Hoo, R. C. L., Mak, W. W. N., Cooper, G. J. S., & Xu, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513907200 · Cited by 256
Self-citationTilg, H., & Moschen, A. R. (2008) · Clinical Science · doi:10.1042/cs20070196 · Cited by 252
Adiponectin, a key adipokine in obesity related liver diseases.
Buechler, C., Wanninger, J., & Neumeier, M. (2011) · PubMed · doi:10.3748/wjg.v17.i23.2801 · Cited by 242
“Adiponectin may also bind to growth factors like PDGF and thereby inhibits binding to their corresponding receptors [71] .”
BackgroundNakajima, T. E., Yamada, Y., Hamano, T., Furuta, K., Matsuda, T., Fujita, S., Kato, K., Hamaguchi, T., & Shimada, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01518.x · Cited by 222
Spranger, J., Verma, S., Göhring, I., Bobbert, T., Seifert, J., Sindler, A. L., Pfeiffer, A., Hileman, S. M., Tschöp, M., & Banks, W. A. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-1077 · Cited by 217
“Although specific transport compounds of adiponectin have not been described yet, binding has been demonstrated with various growth factors such as platelet-derived, fibroblastic, and epidermal growth factors attenuating proliferative properties of adiponectin (38).”
BackgroundBMI and BMD: the potential interplay between obesity and bone fragility
Palermo, A., Tuccinardi, D., Defeudis, G., Watanabe, M., D’Onofrio, L., Lauria Pantano, A., Napoli, N., Pozzilli, P., & Manfrini, S. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060544 · Cited by 197
Taliaferro-Smith, L., Nagalingam, A., Zhong, D., Zhou, W., Saxena, N. K., & Sharma, D. (2009) · Oncogene · doi:10.1038/onc.2009.129 · Cited by 172
“Adiponectin can directly bind certain growth factors to control their bioavailability (Wang et al., 2005).”
Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction
Gu, P., & Xu, A. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-012-9230-8 · Cited by 158
Self-citationRegulation of adiponectin multimerization, signaling and function
Liu, M., & Liu, F. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.06.003 · Cited by 152
“PDGF-BB binds to the HMWandmiddlemolecular weight (MMW, equivalent to the hexameric form) complexes, andbasic FGF preferentially interactswith theHMWform, whereas HB-EGF binds to all three forms with comparable affinities [49].”
InfluentialInflammation, adiponectin, obesity and cardiovascular risk
Mangge, H., Almer, G., Truschnig-Wilders, M., Schmidt, A., Gasser, R., & Fuchs, D. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710794183006 · Cited by 142
Challenges and Perspectives in the Treatment of Diabetes Associated Breast Cancer
Samuel, S. M., Varghese, E., Varghese, S., & Büsselberg, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.004 · Cited by 141
Bariatric surgery, bone loss, obesity and possible mechanisms
Brzozowska, M. M., Sainsbury, A., Eisman, J. A., Baldock, P. A., & Center, J. R. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01050.x · Cited by 128
From obesity to cancer: a review on proposed mechanisms
Tahergorabi, Z., Khazaei, M., Moodi, M., & Chamani, E. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3229 · Cited by 118
“The HMW adiponectin through binding with 3 growth factors including platelet‐derived growth factor (PDGF BB), bFGF, and heparin‐binding epidermal growth factor–like growth factor (HB‐EGF) can exert antiproliferative action by reducing the bioavailability of these growth factors at the prereceptor level.(84)”
BackgroundYau, M.-H., Wang, Y., Lam, K. S. L., Zhang, J., Wu, D., & Xu, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809802200 · Cited by 109
Self-citationAdiponectin: Protection of the endothelium
Lam, K. S. L., & Xu, A. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0019-y · Cited by 94
“In vitro studies also showed that the HMW form bound preferentially to fibroblast growth factor [ 20 ], and was the only oligomeric form that suppressed apoptosis of cultured human umbilical vein endothelial cells [18].”
BackgroundSelf-citationLarsson, S. C., Spyrou, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155326 · Cited by 89
Hammoud, S. H., AlZaim, I., Al-Dhaheri, Y., Eid, A. H., & El-Yazbi, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.707126 · Cited by 87
Obesity associated disease risk: the role of inherent differences and location of adipose depots
Hill, J. H., Solt, C., & Foster, M. T. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0012 · Cited by 79
Liu, Y., Vu, V., & Sweeney, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00842 · Cited by 69
DuPriest, E. A., Lin, B., Kupfer, P., Sekiguchi, K., Bhusari, A., Quackenbush, A., Celebic, A., Morgan, T. K., Purnell, J. Q., & Bagby, S. P. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00162.2017 · Cited by 3
Metadata
- Authors
- Wang, Y., Lam, K. S. L., Xu, J. Y., Lu, G., Xu, L. Y., Cooper, G. J. S., & Xu, A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 280
- Issue
- 18
- Pages
- 18341-18347
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1964814161
- Cited by
- 380
- References
- 45
- FWCI
- 18.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.